Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alphamethadol is a synthetic opioid analgesic and an isomer of dimepheptanol (methadol), with the other being betamethadol. It consists of two stereoisomers, L-α-methadol and D-α-methadol. Both isomers bind to and activate the μ-opioid receptor, producing opioid analgesic effects similar to those of methadone and alphacetylmethadol. Alphamethadol has a high potential for abuse, lacks accepted medical use in the United States, and is classified as a Schedule I controlled substance by the DEA[1][2][3]. L-α-methadol serves as an active metabolite of levacetylmethadol (LAAM), which was previously used in opioid addiction therapy[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alphamethadol.